OssDsign Enrolls First Patient in U.S. PROPEL Registry

The first patient has been enrolled in OssDsign's multi-center, prospective spinal fusion registry in the U.S., PROPEL, with the objective to evaluate the use and outcome of OssDsign Catalyst in real-world clinical practice.

OssDsign Catalyst is a synthetic bone graft designed to help promote bone growth in spinal fusions. Similar to the body’s...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0